References of "DELANAYE, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDiscrepancies between creatinine-based and cystatin C-based equations in estimating prevalence of stage 3 chronic kidney disease in an elderly population.
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Saint-Remy, Annie ULg et al

in Scandinavian Journal of Clinical & Laboratory Investigation (2009), 69(3), 344-9

Background . The prevalence of stage 3 chronic kidney disease (CKD) is increasing, calculated using the modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration ... [more ▼]

Background . The prevalence of stage 3 chronic kidney disease (CKD) is increasing, calculated using the modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration rate (GFR). Cystatin C-based equations are also being used to estimate GFR. Using creatinine-based and cystatin C-based equations, the aim of our study was to measure the difference in prevalence of stage 3 CKD in a population. Methods . CKD screening is organized in the Province of Liege, Belgium. On a voluntary basis, people aged between 45 and 75 years are invited for screening. GFR is estimated using the MDRD study equation and by the three recent cystatin C-based equations proposed by Levey's group. The Levey 1 equation is based on cystatin C only and the Levey 2 equation on cystatin C corrected for age and sex. The Levey 3 equation combines cystatin C, creatinine, age and sex. Results . The population screened comprised 754 people. Cystatin C is highly correlated with creatinine (r = 0.6196, p<0.0001). Prevalence of stage 3 CKD when GFR is estimated by the MDRD equation study is 17.2 %, which is significantly and much higher than the prevalence obtained when cystatin C-based equations are used. Indeed, prevalence is 2 %, 3.3 % and 5.8 % with the Levey 1, 2 and 3 equations, respectively. Conclusions . The prevalence of stage 3 CKD varies strongly following the method used for estimating GFR, creatinine-based or cystatin C-based equations. Such discrepancies must be confirmed and explained in additional studies using GFR measured with a reference method. [less ▲]

Detailed reference viewed: 39 (4 ULg)
Full Text
Peer Reviewed
See detailErrors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum.
Delanaye, Pierre ULg; Mariat, Christophe; Cavalier, Etienne ULg et al

in Nephrology Dialysis Transplantation (2009), 24(12), 3593-6

Detailed reference viewed: 19 (10 ULg)
Full Text
Peer Reviewed
See detailIndexation du debit de filtration glomerulaire par la surface corporelle : mythe et realite
Delanaye, Pierre ULg; Mariat, Christophe; Cavalier, Etienne ULg et al

in Néphrologie & Thérapeutique (2009), 5(7), 614-22

Indexing glomerular filtration rate (GFR) for body surface area (BSA) is often realized without arising any questions. However, physiological basis for such an indexation are very poor. Indeed, indexing ... [more ▼]

Indexing glomerular filtration rate (GFR) for body surface area (BSA) is often realized without arising any questions. However, physiological basis for such an indexation are very poor. Indeed, indexing GFR for BSA to avoid variation due to differences in body size necessarily implies that GFR is a linear function of BSA and that the intercept of this linear function is zero. Moreover, when GFR is indexed for BSA, the relation indexed GFR-BSA must completely disappear. These physiological prerequisites are not found for BSA indexation. We will review the history of this indexation and will underline errors and defaults. Different equations to estimate BSA exist and will be discussed. The choice of "1.73m(2)" will be also criticized. Moreover, indexing GFR for BSA has little impact on GFR results in "normal" body size population. Nevertheless, this indexation will have strong consequences in very lean (such as anorexia) and in obese patients. We will discuss possible alternatives proposed to substitute for BSA indexation. [less ▲]

Detailed reference viewed: 52 (8 ULg)
Full Text
Peer Reviewed
See detailVitamin D: current status and perspectives.
Cavalier, Etienne ULg; Delanaye, Pierre ULg; Chapelle, Jean-Paul ULg et al

in Clinical Chemistry & Laboratory Medicine (2009), 47(2), 120-127

Abstract The role of vitamin D in maintaining bone health has been known for decades. Recently, however, the discovery that many tissues expressed the vitamin D receptor and were able to transform the 25 ... [more ▼]

Abstract The role of vitamin D in maintaining bone health has been known for decades. Recently, however, the discovery that many tissues expressed the vitamin D receptor and were able to transform the 25-OH vitamin D into its most active metabolite, 1,25-(OH)(2) vitamin D, has led to a very promising future for this "old" molecule. Indeed, observational studies, and more and more interventional studies, are raising the importance of a significant vitamin D supplementation for not-only skeletal benefits. Among them, 25-OH vitamin D has been found to play an important role in prevention of cancers, auto-immune diseases, cardiovascular diseases, diabetes, and infections. Vitamin D deficiency, defined as serum 25-OH vitamin D levels <30 ng/mL, is very common in our population. The cost/benefit ratio and some recently published studies are clearly now in favor of a controlled and efficient vitamin D supplementation in these patients presenting a 25-OH vitamin D level <30 ng/mL. More attention should also be focused on pregnant and lactating women, as well as children and adolescents. Clin Chem Lab Med 2009;47. [less ▲]

Detailed reference viewed: 192 (18 ULg)
Full Text
Peer Reviewed
See detailEtude analytique des trois trousses de cystatine C et impact sur les formules basées sur la cystatine pour l'estimation du DFG.
Cavalier, Etienne ULg; Péroni, Laurence; Abshoff, Christelle et al

in Néphrologie & Thérapeutique (2008, November), 4(6), 399-400

Detailed reference viewed: 45 (8 ULg)
Full Text
Peer Reviewed
See detailAnalytical Validation of Diasorin Liaison and Roche Elecsys Methods for the Determination of Osteocalcin
Cavalier, Etienne ULg; Delanaye, Pierre ULg; Carlisi, Ignazia ULg et al

in Journal of Bone and Mineral Research (2008, September), 23

Detailed reference viewed: 193 (10 ULg)
Full Text
Peer Reviewed
See detailL'insuffisance rénale et sa prise en charge
Krzesinski, Jean-Marie ULg; DELANAYE, Pierre ULg; Smelten, Nicole ULg et al

in Revue Médicale de Liège (2008, March 13)

Chronic kidney disease is a worldwide growing problem, especially nowadays due to 3 factors very often encountered together (old age, diabetes mellitus and arterial hypertension) A multidisciplinary ... [more ▼]

Chronic kidney disease is a worldwide growing problem, especially nowadays due to 3 factors very often encountered together (old age, diabetes mellitus and arterial hypertension) A multidisciplinary approach is needed to reduce this epidemic with important health implication. This needs of course well trained health partners. On the occasion of the world kidney day on March 2008, five lectures were given on the topic. The lecturers have insisted on the up to date management of chronic kidney insufficiency, a serious problem of public health. [less ▲]

Detailed reference viewed: 65 (5 ULg)
Full Text
Peer Reviewed
See detailFalse positive PTH results: An easy strategy to test and detect analytical interferences in routine practice
Cavalier, Etienne ULg; Carlisi, Agnès; Chapelle, Jean-Paul ULg et al

in Clinica Chimica Acta (2008), 387(1-2), 150-152

Background: As other immunoassays, PTH determination is not free from interferences. Indeed, natural antibodies like heterophile antibodies (HAMA) and rheumatoid factor (RF) can induce falsely elevated ... [more ▼]

Background: As other immunoassays, PTH determination is not free from interferences. Indeed, natural antibodies like heterophile antibodies (HAMA) and rheumatoid factor (RF) can induce falsely elevated results, leading to misdiagnosis and expensive unnecessary explorations. However, in routine practice, these interferences are not always obvious to detect. Methods: On 2084 PTH samples, we applied a validation strategy in four steps to screen for HAMA and rheumatoid factor interferences. Results: 36% of our samples presented an elevated PTH. We found a clinically plausible reason for 91% of them. The remaining 63 suspicious samples were treated with HBT and 40% of them were found to be HAMA positive. RF determination was performed on the HAMA-negative samples and RE was positive in 21 of them. They were then treated with RF-Absorbent. Nine of these 21 samples presented RE interference. Conclusion: Applying this strategy in our routine validation, we managed to avoid spuriously elevated PTH results, which could have caused medical errors as well as unnecessary cost-effective extra-investigations. (c) 2007 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 76 (6 ULg)
Full Text
Peer Reviewed
See detailCystatine C: point d'etape et perspectives.
Seronie-Vivien, Sophie; Delanaye, Pierre ULg; Pieroni, Laurence et al

in Annales de Biologie Clinique (2008), 66(3), 301-23

Cystatin C is a low molecular weight-protein, which may replace creatinine for the evaluation of renal function, particularly in the clinical settings where the relationship between creatinine production ... [more ▼]

Cystatin C is a low molecular weight-protein, which may replace creatinine for the evaluation of renal function, particularly in the clinical settings where the relationship between creatinine production and muscular mass impairs the clinical performance of creatinine. This paper intends to summarize the current knowledge about the physiology of cystatin C and about its use as a renal marker, alone or within formulas developed to estimate the glomerular filtration rate. Moreover, this paper reviews the recent data about potential other applications of cystatin C, especially in cardiology, in oncology and in clinical pharmacology. [less ▲]

Detailed reference viewed: 79 (2 ULg)
Full Text
Peer Reviewed
See detailCystatin C: current position and future prospects.
Séronie-Vivien, Sophie; Delanaye, Pierre ULg; Piéroni, Laurence et al

in Clinical Chemistry & Laboratory Medicine (2008), 46(12), 1664-1686

Abstract Cystatin C is a low-molecular-weight protein which has been proposed as a marker of renal function that could replace creatinine. Indeed, the concentration of cystatin C is mainly determined by ... [more ▼]

Abstract Cystatin C is a low-molecular-weight protein which has been proposed as a marker of renal function that could replace creatinine. Indeed, the concentration of cystatin C is mainly determined by glomerular filtration and is particularly of interest in clinical settings where the relationship between creatinine production and muscle mass impairs the clinical performance of creatinine. Since the last decade, numerous studies have evaluated its potential use in measuring renal function in various populations. More recently, other potential developments for its clinical use have emerged. This review summarises current knowledge about the physiology of cystatin C and about its use as a renal marker, either alone or in equations developed to estimate the glomerular filtration rate. This paper also reviews recent data about the other applications of cystatin C, particularly in cardiology, oncology and clinical pharmacology. Clin Chem Lab Med 2008;46:1664-86. [less ▲]

Detailed reference viewed: 81 (4 ULg)
Full Text
Peer Reviewed
See detailImpact de la stabilité de la cystatine C sur la validité des mesures dans les études rétrospectives
Piéroni, Laurence; Delanaye, Pierre ULg; Abshoff, Christelle et al

in Néphrologie & Thérapeutique (2008), 4(6), 052

Detailed reference viewed: 43 (7 ULg)
Full Text
Peer Reviewed
See detailAnalytical study of three cystatin C assays and their impact on cystatin C-based GFR-prediction equations.
Delanaye, Pierre ULg; Pieroni, Laurence; Abshoff, Christelle et al

in Clinica Chimica Acta (2008), 398(1-2), 118-24

BACKGROUND: Cystatin C-based equations are used to estimate GFR. However, three cystatin C immunoassays are on the market. Difference in cystatin C assays could have strong consequences on the accuracy ... [more ▼]

BACKGROUND: Cystatin C-based equations are used to estimate GFR. However, three cystatin C immunoassays are on the market. Difference in cystatin C assays could have strong consequences on the accuracy and precision of cystatin C-based equations. We have performed an analytical study of these three assays and studied potential differences between assays on the precision of cystatin C-based equations. METHODS: We have studied imprecision, recovery, linearity and interferences of the three immunoassays (nephelometric assay from Siemens and turbidimetric assays from Dako and Gentian). The impact of differences in cystatin C assays has been studied for the equations published by Levey (Siemens assay) and Grubb (Dako assay). RESULTS: Analytical performance of the Dako assay is slightly less high. For cystatin C values below 2.5 mg/L, no statistical difference is found between results given by the Dako and the Gentian assays. So, both assays can be used in the Grubb equation. Cystatin C results are different with the Siemens assay. The Levey equation, built with the Siemens assay, can only be used with cystatin C values measured with this assay. Using the Dako or Gentian assay results in the Levey equation can lead to differences in estimating GFR up to 6 mL/min/1.73 m2. Differences can reach 9.5 mL/min/1.73 m2 if the Siemens assay is used in the Grubb equation. CONCLUSION: The Siemens and Gentian assays seem analytically more valid than the Dako assay for cystatin C determination. Differences in cystatin C assays can lead to significant differences in cystatin C-based equations. However, these differences seem less important than the differences observed with creatinine and creatinine-based equations. [less ▲]

Detailed reference viewed: 35 (10 ULg)
Full Text
Peer Reviewed
See detailNew data on the intraindividual variation of cystatin C.
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Depas, Gisèle ULg et al

in Nephron. Clinical Practice (2008), 108(4), 246-8

BACKGROUND: Cystatin C is a new interesting marker of glomerular filtration rate (GFR). However, data regarding its biological variance are scarce and conflicting. The ability of cystatin C to ... [more ▼]

BACKGROUND: Cystatin C is a new interesting marker of glomerular filtration rate (GFR). However, data regarding its biological variance are scarce and conflicting. The ability of cystatin C to longitudinally follow renal function in patients therefore remains questionable. METHODS: 12 healthy subjects (6 men and 6 women) were included in the final statistical analysis. Serum creatinine, plasma cystatin C and GFR were measured twice after a 1-week interval on the same day, at the same time, and under the same preanalytical and analytical conditions. GFR was measured with an iohexol method. Serum creatinine was measured with a compensated Jaffe and an enzymatic method. Plasma cystatin C was measured by a particle-enhanced immunonephelometric method. Analytical (CV(A)) and within-subject (CV(I)) variances were classically calculated. RESULTS: CV(A) for creatinine (Jaffe and enzymatic methods) and cystatin C was 2.5, 0.97 and 1.29%, respectively. CV(I) was 5.8, 5 and 4.5% for the Jaffe creatinine, enzymatic creatinine and cystatin C determinations, respectively. CONCLUSION: Our study confirms that intraindividual variation of cystatin C and creatinine are similar. Therefore, from a biological point of view, cystatin C seems as accurate as creatinine for the longitudinal follow-up of renal function in daily clinical practice. [less ▲]

Detailed reference viewed: 41 (5 ULg)